Peptide News Digest

#Consumer-Advocacy

1 story

Regulatory · View digest

Public Citizen 'Outrage of the Month' July 2026: The FDA, Peptides, and RFK Jr. — Advocacy Group Argues 'No Credible Reason' Peptides Deemed Unproven and Unsafe in 2023 Are Now Miraculously Safe, Warns Panel Composition Risks Rubber-Stamping HHS Secretary Kennedy's Wishes

Public Citizen, the consumer advocacy organization founded by Ralph Nader in 1971, published its July 2026 'Outrage of the Month' column titled 'The FDA, Peptides and RFK Jr.' The piece argues that when the FDA banned compounding of nineteen peptides in 2023, it cited immunogenicity risks for certain routes of administration, impurity concerns, and lack of sufficient information to know whether the drugs would cause harm when administered to humans. The advocacy position: 'There is no credible reason to believe that peptides deemed unproven or unsafe in 2023 are now miraculously safe and effective.' Public Citizen also raised concerns about the eight new PCAC panelists named Monday June 29, warning that the committee could be filled with members who would 'rubber stamp Kennedy's wishes' rather than substantively review the FDA staff briefing documents concluding the seven peptides have insufficient evidence for 503A bulks list eligibility. The piece adds to a June-July critic chorus that includes STAT News (panelist conflicts), NBC News + NPR + Washington Post (FDA scientists disagree with RFK Jr.), and BioCentury (peptide deregulation threatens drug-safety foundations).